Tilray Brands, Inc., a company specialising in cannabis and consumer packaged goods, today announced progression in the medical cannabis industry in Portugal.
Following the successful approval of Tilray whole flower THC 18, Tilray Medical has now received approval for the first medical cannabis extract, Tilray Oral Solution THC 5 CBD 20, in Portugal.
This marks a significant milestone in medical cannabis availability and patient care within the country.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, Inc., said: "This is a great step forward for patient care in Portugal. With the approval of our first medical cannabis extract, we are proud to be engrossed in medical cannabis research.”
The newly approved medical cannabis extract is set to launch in late spring, offering new therapeutic options for patients across Portugal with specified medical conditions. The approved extract is indicated for use in several critical areas of patient care.
